Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of “Reduce” by Analysts

Posted by Stanley Muller on May 13th, 2026

Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) has earned an average recommendation of “Reduce” from the five research firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $1.8333.

PACB has been the subject of a number of research analyst reports. Zacks Research downgraded shares of Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 20th. Barclays increased their price target on shares of Pacific Biosciences of California from $1.00 to $1.50 and gave the stock an “underweight” rating in a research note on Monday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research note on Tuesday, April 21st.

Get Our Latest Research Report on Pacific Biosciences of California

Pacific Biosciences of California Stock Performance

Shares of NASDAQ:PACB opened at $1.28 on Wednesday. The company has a market cap of $397.57 million, a PE ratio of -2.98 and a beta of 2.40. Pacific Biosciences of California has a 52 week low of $0.85 and a 52 week high of $2.73. The firm has a 50 day simple moving average of $1.46 and a 200 day simple moving average of $1.82.

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Pacific Biosciences of California had a negative net margin of 80.35% and a negative return on equity of 571.06%. The company had revenue of $37.18 million during the quarter, compared to the consensus estimate of $39.94 million. On average, equities analysts predict that Pacific Biosciences of California will post -0.54 earnings per share for the current year.

Insider Activity at Pacific Biosciences of California

In related news, insider Michele Farmer sold 35,215 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $1.58, for a total value of $55,639.70. Following the transaction, the insider directly owned 234,044 shares in the company, valued at approximately $369,789.52. This trade represents a 13.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Christian O. Henry sold 331,793 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $1.58, for a total transaction of $524,232.94. Following the completion of the transaction, the insider owned 2,814,374 shares in the company, valued at $4,446,710.92. The trade was a 10.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 729,711 shares of company stock worth $1,161,951. 2.40% of the stock is owned by insiders.

Institutional Trading of Pacific Biosciences of California

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Creative Planning raised its position in shares of Pacific Biosciences of California by 245.9% during the second quarter. Creative Planning now owns 175,690 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 124,893 shares during the last quarter. Cetera Investment Advisers lifted its stake in shares of Pacific Biosciences of California by 10.1% in the second quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 9,617 shares during the period. Prudential Financial Inc. grew its position in Pacific Biosciences of California by 73.0% during the second quarter. Prudential Financial Inc. now owns 35,684 shares of the biotechnology company’s stock worth $44,000 after buying an additional 15,062 shares in the last quarter. Invesco Ltd. increased its stake in Pacific Biosciences of California by 60.0% during the second quarter. Invesco Ltd. now owns 839,340 shares of the biotechnology company’s stock valued at $1,041,000 after acquiring an additional 314,697 shares during the period. Finally, HUB Investment Partners LLC bought a new position in Pacific Biosciences of California during the second quarter valued at about $77,000.

About Pacific Biosciences of California

(Get Free Report)

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.